Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Healing of duodenal ulcers
* Maintenance of healing of erosive esophagitis and duodenal ulcers
* H. pylori eradication (in combination with antibiotics)
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. A subsequent 8-week course may be considered for patients not healed.
* **Maintenance of healing:** 40 mg orally once daily.
* **Duodenal ulcers:** 40 mg orally once daily for 7 to 25 days.
* **H. pylori eradication:** 40 mg orally twice daily for 7 to 14 days in combination with amoxicillin 1000 mg BID and clarithromycin 500 mg BID, or with clarithromycin 500 mg BID and metronidazole 500 mg BID.
* **Pathological hypersecretory conditions:** Starting dose typically 40 mg orally or intravenously twice daily, may be increased as needed. Doses up to 240 mg daily have been administered.
## Pediatric Dosing
* **1 to 5 years:** 10 mg orally once daily for GERD.
* **5 to 16 years:** 20 mg orally once daily for GERD.
* **Dosing for erosive esophagitis or H. pylori eradication in pediatric patients is not well-established and should follow specific guidelines or expert consultation.**
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily. IV formulations are not recommended in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less Common: Arthralgia, fatigue, elevated liver enzymes.
Serious: *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia (potentially severe), vitamin B12 deficiency, lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Drugs Dependent on Gastric pH:** PPIs can decrease absorption of drugs requiring an acidic environment (e.g., ketoconazole, itraconazole, atazanavir, nelfinavir, iron salts).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution with drugs like clopidogrel, citalopram, escitalopram, diazepam, and phenytoin.
* **Warfarin:** Potential for increased INR and bleeding risk. Monitor INR closely.
## Monitoring
* Magnesium levels (especially with prolonged use or concomitant diuretic use).
* Bone mineral density (consider screening in patients at risk for osteoporosis with long-term therapy).
* Signs and symptoms of *C. difficile* infection.
* Vitamin B12 levels (with prolonged therapy).
## Clinical Pearls
* Oral pantoprazole is generally taken 30-60 minutes before a meal.
* IV administration is typically used when oral intake is not possible.
* Long-term PPI use has been associated with increased risk of certain adverse events; weigh risks and benefits.
* Consider step-down therapy or intermittent use in patients with GERD once symptoms are controlled.
---
*Please verify the current prescribing information and local institutional protocols for the most up-to-date dosing and safety recommendations.*
